email article
Transgender patients undergoing gender-affirming surgery were not at significant risk for perioperative venous thromboembolism (VTE) whether or not hormone therapy was stopped before surgery, researchers reported.
In a retrospective study that included 407 transgender patients undergoing vaginoplasty, no VTE events occurred in those who continued hormone therapy through surgery, said John Pang, MD, of the Mount Sinai Center for Transgender Medicine and Surgery in New York City, and colleagues.
Reporting online in the
Journal of Clinical Endocrinology and Metabolism, the team said the only VTE event in the study occurred in the group that stopped hormone therapy prior to surgery.